SMTI

Over the past six months, Sanara MedTech's stock price has declined. In March 2026, the company reported its Fourth Quarter and Full Year 2025 Financial Results, and reaffirmed its Full Year 2026 Financial Guidance. In November 2025, the company announced a strategic realignment to focus on its surgical business, discontinuing the operations of its Tissue Health Plus (THP) segment. In October 2025, Sanara MedTech was noted as a "bottom market performer" with its stock experiencing a decline. In August 2025, the company reported its second-quarter 2025 financial results, showing a 28% increase in net revenue year-over-year, but still recorded a net loss. In July 2025, insiders suffered losses following a decline in share price. Sanara MedTech Inc. is scheduled to report its First Quarter 2026 Financial Results in May 2026.